Cannabidiol (CBD) has quickly surfaced as one of the most versatile and effective medical treatments around. From simple ailments such as pain and inflammation to severe conditions such as diabetes and epilepsy, CBD has proven to be effective at managing a variety of disorders. Despite the plethora of anecdotal evidence on the efficacy of CBD, there has been limited scientific research on the matter, and due to this, medical professionals have been slow to recommend the product to their patients.
Amber Nelson, a mother from Cedar Rapids, Iowa, has been struggling to find help for her autistic son. She says that they have tried alternative treatments for the young boy, Dominic, but he is highly aggressive and has a tough time with transition. She and other Iowa parents have been struggling to find local doctors who approve of medical CBD. Finding help for Dominic has not been easy, she says. She’s even tried a patch of medication, and some doctors also recommended ADHD medication. “It turned my son into a zombie,” she says.
She first heard of CBD three years ago, and after trying the oil, she saw a change in her son. Autistic kids often have high levels of anxiety, and according to Nelson, her son was a little more mellow and relaxed after taking CBD. However, when she turned to local doctors to approve the medical CBD, she ran into walls.
Last year’s Farm Bill legalized the cultivation of hemp, and by extension, CBD. In Iowa, it qualifies as a medical treatment for 13 medical conditions. They are; cancer, seizures, Crohn’s disease, intractable pain, multiple sclerosis with severe and persistent muscle spasms, AIDS, Parkinson’s disease, and severe, intractable pediatric autism with self-injurious or aggressive behavior.
Despite severe pediatric autism qualifying for medical CBD treatment, the doctors Nelson approached refused to sign off on the paperwork, citing lack of enough knowledge on CBD as the reason. Iowa’s Department of Public Health states that from October, health practitioners certified 854 patients for medical CD treatment, but less than one percent of them suffered from autism.
Nelson says that she’s found a children’s hospital in Des Moines, and she’s holding out hope that her son will get the help he needs. But that isn’t enough. There are tons of parents with autistic children who know that CBD can help alleviate the symptoms. Nelson pleads for easier access to medical CBD for kids like hers who desperately need the help. “We want to be able to give our kids another form of treatment to help them live the best life they can.”
Analysts believe such accounts as that of Amber Nelson break the hearts of CBD companies like Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) and Willow Biosciences Inc. (CSE: WLLW) that work tirelessly to develop products to benefit people from different walks of life.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com